Gavin MacBeath
Vermögen: 48 772 $ am 30.06.2026
Vermögen: 48 772 $ am 30.06.2026
Gavin MacBeath was the founder of Merrimack Pharmaceuticals, Inc., founded in 1993, where the title held was Head-Translational Medicine from 2016 to 2017.
Dr. MacBeath is currently Chief Executive Officer & Director at TScan Therapeutics, Inc. since 2023, with the job starting in 2018.
Former jobs include Chief Scientific Officer at Abpro Corp.
from 2017 to 2018 and Associate Professor at Harvard University from 2002 to 2010.
Education includes a doctorate from The Scripps Research Institute conferred in 1997 and an undergraduate degree from the University of Manitoba conferred in 1991.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 49’767 ( 0.08% ) | 48 772 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Vorstandsvorsitzender | 28.03.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
| ABPRO CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2018 |
| MERRIMACK PHARMACEUTICALS | Gründer | 01.09.2017 |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.06.2010 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Abpro Corp.
Abpro Corp. BiotechnologyHealth Technology Develops antibody therapies | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer | Health Technology |
University of Manitoba
University of Manitoba Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen